

CANNABIS COMPLIANCE BOARD

STATE OF NEVADA

ccb.nv.gov

CARSON CITY OFFICE
3850 Arrowhead Drive, Suite 100
Carson City, Nevada 89706
Main Line: (775) 687-6299

LAS VEGAS OFFICE
700 East Warm Springs Road, Suite 100
Las Vegas, Nevada 89119

JAMIE HUMM
Executive Director

MICHAEL MILLES
Deputy Director

MAJ. GEN. ONDRA BERRY, (RET.)
Chair



JOE LOMBARDO
Governor

SMALL BUSINESS IMPACT STATEMENT AS REQUIRED BY NRS 233B.0608

Nevada Cannabis Compliance Regulations

1. Background

The Cannabis Compliance Board drafted proposed changes to the Nevada Cannabis Compliance Regulations (“NCCR”) 1, 10 and 11 to incorporate changes from the 2025 legislative session, which clarifies definitions, adopts certain laboratory sampling and testing standards pursuant to Senate Bill 157 (2025), and to provide other matters properly relating thereto. The first workshop to discuss the proposed changes, held on November 19, 2025, identified additional suggested changes, and a second workshop was scheduled for March 3, 2026.

2. A description of the way comments were solicited from affected small businesses, a summary of their responses, and an explanation of the manner in which other interested persons may obtain a copy of the summary.

Prior to conducting the small business impact survey, the CCB received input on possible proposed guidelines and changes with key industry stakeholders. As there was no consensus as to a starting point, the CCB used the ASTM standard as referenced in Senate Bill 157.

On January 27, 2026, the Cannabis Compliance Board (“Agency”) notified the public by posting a notice of workshop and proposed language on the CCB website.

Draft language provided proposed changes to the following NCCRs:

- Regulation 1. Issuance of Regulations; Construction; Definitions
- Regulation 10. Minimum Good Manufacturing Practices for Cultivation and Preparation of Cannabis and Cannabis Products for Administration to Humans
- Regulation 11. Cannabis Independent Testing Lab

Respondents were asked whether the changes to Regulations 1, 10, and 11 would have a direct or indirect adverse impact to their business, a direct or indirect beneficial impact on their business, or whether they were “not affected” or “unsure” of the impact on their business. Those results are further detailed by each regulation as follows:

Regulation 1.125 Adverse Impact

Nine individuals (47% of respondents) indicated a potential adverse economic impact. 53% responded no or unsure/not affected.

Explanations included:

- An increased lot size will decrease number of tests ordered and therefore affect cost of testing (4 respondents).
- Required documentation and sampling requirements would create additional administrative burdens (4 respondents).
- Lot size changes may create an increased burden for entry into industry.

Regulation 1.125 Indirect Adverse Impact

Five individuals (26% of respondents) indicated a potential indirect adverse economic impact. 74% responded no or unsure/not affected.

Explanations included:

- Additional administrative burdens for laboratories or downstream production facilities (2 respondents).
- May result in disproportionate increase in testing costs for smaller cultivators (2 respondents).
- Smaller sample sizes may increase the risk of missed contaminants.
- Additional costs may incentivize falsified lab testing or practices.
- Adoption of the standard by direct reference would leave no opportunity for agency review and amendment or would otherwise introduce conflicts with other case law.

Regulation 1.125 Beneficial Impact

Three individuals (16% of respondents) indicated a potential beneficial impact. 84% responded no or unsure/not affected.

Explanations included:

- Changes to lot sizes may lower overhead expenses and lower number of tests ordered and may result in cost savings (2 respondents)

Regulation 1.125 Indirect Beneficial Impact

One individual (5% of respondents) indicated a potential indirect beneficial effect. 95% responded no or unsure/not affected.

Explanations included:

- Fewer tests may lessen time to receive results.

Regulation 11.030(15),11.050, 11.070 Adverse Impact

Eight individuals (42% of respondents) indicated a potential adverse impact. 58% responded no or unsure/not affected.

Explanations included:

- A potential increase in costs for quality assurance testing (3 respondents).
- Increased sample amounts may increase wasted product after testing (2 respondents).
- Small sample size may introduce statistical uncertainty for results (3 respondents).
- Documentation would create an increased administrative burden (2 respondents).

Regulation 11.030(15),11.050, 11.070 Indirect Adverse Impact

Six individuals (32% of respondents) indicated a potential indirect adverse impact. 68% answered no or unsure/not affected.

Explanations included:

- There may be increased cost for compliance testing (3 respondents).
- Increased administrative burden for required documentation (2 respondents).
- Concern regarding statistical viability of results based on sample size.
- Additional costs may incentivize falsified lab testing or practices.

Regulation 11.030(15),11.050, 11.070 Beneficial Impact

Two individuals (11% of respondents) indicated a potential beneficial impact. 89% responded no or unsure/not affected.

Explanations included:

- May result in a reduction of testing costs.

Regulation 11.030(15),11.050, 11.070 Indirect Beneficial Impact

One individual (5% of respondents) indicated a potential indirect beneficial impact. 95% responded no or unsure/not affected.

Explanations included:

- May result in a reduction of testing costs.

6. **The estimated cost to the agency for enforcement of the proposed regulations.**

The proposed permanent regulations present no significant foreseeable or anticipated cost for enforcement. To the extent sampling protocols and documentation requirements are changing, regulatory staff will incorporate these into their standard inspection and audit procedures, and the Agency does not anticipate that this will affect a major change.

7. **If the proposed regulations provide a new fee or increases to existing fees, the total annual amount the agency expects to collect and the manner in which the money will be used.**

The proposed regulations do not increase or introduce new fees.

8. **If the proposed regulations include provisions which duplicate or are more stringent than federal, state or local standards regulating the same activity, an explanation of why such duplicative or more stringent provisions are necessary.**


The proposed permanent regulations do not overlap or duplicate any regulation of other federal, State or local governmental entities, but does reference regulatory authority granted by NRS 678A through NRS 678D and reference standards by the American Society for Testing and Materials.

9. **The reasons for the conclusion of the agency regarding the impact of these regulations on small businesses.**

The Agency cannot determine the impact to small cannabis businesses as comments were received that predict both increases and decreases in costs to quality assurance testing. The potential adoption of this change may or may not provide a benefit but would be dependent on specific facility operations and license type.

I hereby certify, to the best of my knowledge or belief, a concerted effort was made to determine the impact of the proposed regulations on small businesses and that this statement was properly prepared, and the information contained herein is accurate.

Dated this 12th day of February 2026.



James Humm
Executive Director
Nevada Cannabis Compliance Board

To receive a printed copy of this Small Business Impact Statement, contact:

Attn: Small Business Impact Summary – 02/09/26
Cannabis Compliance Board
700 E. Warm Springs Road #100
Las Vegas, Nevada 89119
Email: regulations@ccb.nv.gov